Thompson A S, Fan J Y, Sun D, Hansen M, Hurley L H
Drug Dynamics Institute, College of Pharmacy, University of Texas at Austin 78712, USA.
Biochemistry. 1995 Sep 5;34(35):11005-16. doi: 10.1021/bi00035a006.
Bizelesin (formerly U77,779, The Upjohn Co.) is a bifunctional DNA cross-linking antitumor antibiotic consisting of two open-ring homologs of the (+)-CC-1065 cyclopropa[c]pyrrolo[3,2-e]indol-4(5H)-one (CPI) subunits connected by a rigid linking moiety. Previous studies have shown that Bizelesin most often forms an interstrand cross-link through the N3 of two adenines 6 base pairs (bp) apart (inclusive of the modified adenines). However, gel electrophoresis studies have also indicated that Bizelesin forms 7-bp cross-links in specific sequences. In most of these sequences the cross-linked adenines represent the only possible cross-link site (i.e., no 6-bp site is available); however, in several sequences, a 7-bp sequence is selected in overwhelming preference to a possible 6-bp sequence. In this study, we demonstrate the unique requirement for a G.C base pair within this sequence and the critical presence of the exocyclic 2-amino group of guanine. In a subsequent two-dimensional 1H-NMR study that concentrates on the 7-bp cross-link formed with the sequence 5'-TTAGTTA-3', the role of the central G.C base pairs in the formation of a 7-bp cross-link is probed. 1H-NMR analysis coupled with restrained molecular dynamics (rMD) provides evidence for distortion around the covalently modified adenines. Because of this distortion, the modified bases are twisted toward the center of the duplex adduct, effectively reducing the cross-linked distance. The rMD study also indicates that a hydrogen bond is formed between the exocyclic amine of the central guanine and the carbonyl of the ureylene linker. On the basis of the observation of the distortion in the duplex and the hydrogen bonding between the drug and DNA, it is possible to speculate on the role of the central G.C bases in this sequence preference and propose a mechanism by which Bizelesin forms a 7-bp rather than a 6-bp cross-link with this sequence.
比泽利辛(原名U77,779,由Upjohn公司生产)是一种双功能DNA交联抗肿瘤抗生素,由两个开环的(+)-CC-1065环丙[c]吡咯并[3,2-e]吲哚-4(5H)-酮(CPI)亚基的同系物通过一个刚性连接部分相连组成。先前的研究表明,比泽利辛最常通过相距6个碱基对(bp)(包括修饰的腺嘌呤)的两个腺嘌呤的N3形成链间交联。然而,凝胶电泳研究也表明,比泽利辛在特定序列中形成7-bp交联。在这些序列中的大多数中,交联的腺嘌呤代表唯一可能的交联位点(即没有6-bp位点可用);然而,在几个序列中,7-bp序列被压倒性地优先选择,而不是可能的6-bp序列。在本研究中,我们证明了该序列中对G.C碱基对的独特需求以及鸟嘌呤外环2-氨基的关键存在。在随后一项专注于与序列5'-TTAGTTA-3'形成的7-bp交联的二维1H-NMR研究中,探究了中心G.C碱基对在形成7-bp交联中的作用。1H-NMR分析与受限分子动力学(rMD)相结合,为共价修饰的腺嘌呤周围的扭曲提供了证据。由于这种扭曲,修饰的碱基向双链加合物的中心扭曲,有效地缩短了交联距离。rMD研究还表明,中心鸟嘌呤的外环胺与亚甲二氧基连接体的羰基之间形成了氢键。基于对双链体中扭曲以及药物与DNA之间氢键的观察,可以推测该序列偏好中中心G.C碱基的作用,并提出比泽利辛与该序列形成7-bp而非6-bp交联的机制。